Cytek Q2 revenue $46.6M, -6% YoY; net loss widens to $10.4M

Cytek Biosciences, Inc.

Revenue $46.6M (-6% YoY, +4% QoQ); GAAP gross margin 55% (adjusted 58%).
Net loss $10.4M vs $4.4M in Q2 2023; operating loss $8.5M vs $9.1M.
Adjusted EBITDA $2.9M vs $1.5M; cash and securities $277.2M.
FY2024 revenue guidance narrowed to $203-210M (5-9% growth); expects positive cash flow from ops.
Repurchased $2.7M of stock; total installed base 2,656 instruments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.